Marco Pappagallo

Corporate Officer/Principal chez Sapienza University of Rome

Profil

Marco Pappagallo is the founder of Novapharm Therapeutics, which was founded in 2010.
He held the title of Chief Medical Officer at Novapharm Therapeutics.
Currently, Dr. Pappagallo is a Professor at Sapienza University of Rome.
In the past, he worked as the Director-Chronic Pain at Beth Israel Medical Center, The Johns Hopkins University, and Icahn School of Medicine at Mount Sinai.
He also served as the Director-Pain Research & Professor-Anesthesiology at The Mount Sinai Medical Center, Inc. Additionally, Dr. Pappagallo worked as the Executive Director-Medical Intelligence at Grünenthal USA, Inc. and as a Professor at Albert Einstein College of Medicine, Inc. He was also the Chief Medical Officer at Cersci Therapeutics, Inc. Currently, Dr. Pappagallo is the Chief Clinical Officer at Relmada Therapeutics, Inc. from 2020 to 2023.
Dr. Pappagallo obtained a doctorate degree from The American University of Rome.

Postes actifs de Marco Pappagallo

Sociétés	Poste	Début
Sapienza University of Rome	Corporate Officer/Principal	-

Anciens postes connus de Marco Pappagallo

Sociétés	Poste	Fin
RELMADA THERAPEUTICS, INC.	Directeur Technique/Scientifique/R&D	01/01/2023
Albert Einstein College of Medicine, Inc.	Corporate Officer/Principal	01/01/2014
The Mount Sinai Medical Center, Inc.	Corporate Officer/Principal	-
The Johns Hopkins University	Corporate Officer/Principal	-
Icahn School of Medicine at Mount Sinai	Corporate Officer/Principal	-

Formation de Marco Pappagallo

The American University of Rome

Doctorate Degree